Insulin-Resistant Hyperglycemia Induced by Clozapine

Исаков, И. Д.; Klesmer, Jordan; Masand, Prakash S.

doi:10.1176/appi.psy.41.4.373

Cited by 14 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The development of new-onset diabetes or the worsening of preexisting diabetes in patients receiving the atypical neuroleptic, clozapine, has also been reported in numerous case reports (Isakov, Klesmer, & Masand, 2000;Kamran et al, 1994;Kostakoglu et al, 1996;Koval, Rames, & Christie, 1994;Mohan et al, 1999;Peterson & Byrd, 1996;Popli et al, 1997;Rigalleau et al, 2000;Smith, Kenney-Herbert, & Knowles, 1999;Wirshing et al, 1998;Wu et al, 2000).…”

mentioning

confidence: 89%

Prevalence of Diabetes Mellitus in Patients Receiving Depot Neuroleptics or Clozapine

Miller

Molla

2005

Archives of Psychiatric Nursing

View full text Add to dashboard Cite

mentioning

confidence: 89%

Prevalence of Diabetes Mellitus in Patients Receiving Depot Neuroleptics or Clozapine

Miller

Molla

2005

Archives of Psychiatric Nursing

View full text Add to dashboard Cite

“…Several arguments support the onset of DM in patients on atypical antipsychotics being a drug-related effect: ± development of DM within a few days [10,76,92] or weeks [37,42,48,56,73,74,77,78,85,87,89,96] of exposure; ± disappearance of hyperglycemia after discontinuation of the drug and recurrence after reintroduction [10,18,26,49,96]; ± a correlation between the risk of DM and the period of exposure to the drug [14,38]; ± lack of risk factors for DM in part of the patients developing DM [10,33,62,77,87,89]; ± DM onset at a relatively young age.…”

Section: Is It Really a Drug-related Effect?mentioning

confidence: 99%

“…Twenty-one cases were reported as reversible after discontinuation of the atypical[8,18,26,30,33,41,42,48,52,56,73,77] [80,81,86,87,89], but seven cases were not reversible[33,67,74] [77,84,99]…”

mentioning

confidence: 99%

Atypical Antipsychotics and New Onset Diabetes mellitus

2004

Pharmacopsychiatry

View full text Add to dashboard Cite

During the last few years, several case reports and studies have been published on the potential diabetes mellitus (DM)-inducing effect of some atypical antipsychotics, especially clozapine and olanzapine. The purpose of our study was to evaluate diabetogenic effects of atypical antipsychotics in the literature. In order to give a full-scale overview, both peer-reviewed publications and oral and poster presentations on this subject were screened. We found 27 case reports of new-onset DM for clozapine, 39 for olanzapine, 4 for risperidone, and 3 for quetiapine. Related to the year of introduction of these drugs on the market and the number of treatment days of each drug during the last 6 years in 13 western countries, Brazil, and Japan, the cases show an over-representation of cases related to olanzapine and clozapine. In the majority of cases, risk factors (DM family history, obesity, Negroid ethnicity) were present. Eighty-four percent of the cases arose in patients < 50 years, in contrast to the general population (most cases, > 50 years). Comparative epidemiological studies point in the same direction, with two studies showing no differences between the atypical drugs. Antipsychotic agents are used often for treatment of schizophrenia, a condition that appears to be associated with DM also in untreated subjects. Some antipsychotics appear to induce new-onset diabetes mellitus. In view of the health risks of DM and the predisposition in patients with schizophrenia, it is advised to be cautious with prescription of antipsychotics that are associated with new-onset DM. Especially in predisposed patients (family history of DM, obese, Negroid ethnicity), reticence in this respect is required. Moreover, careful monitoring of weight, BMI, and glucose levels is advised both before these antipsychotics are prescribed and during treatment.

show abstract

“…[1][2][3][4] While effective, the agents have repeatedly been shown to cause mild hyperglycemia and hypertriglyceridemia. [5][6][7][8][9][10][11] Although the effects on glucose and lipid metabolism are well documented, the range of glucose and lipid abnormalities is less well characterized. In some individuals, initiation of treatment has been shown to induce latent diabetes, ketoacidosis, and hyperosmolar coma.…”

mentioning

confidence: 99%